Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Drugs during pregnancy and lactation [[electronic resource] ] : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer
| Drugs during pregnancy and lactation [[electronic resource] ] : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; New York, : Elsevier, 2007 |
| Descrizione fisica | 1 online resource (907 p.) |
| Disciplina | 618.32 |
| Altri autori (Persone) | SchaeferChristof |
| Soggetto topico |
Pregnant women - Drug use
Pregnant women - Medical care Obstetrical pharmacology Fetus - Effect of drugs on Newborn infants - Effect of drugs on |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-281-01913-5
9786611019136 0-08-054977-2 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders
1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective β[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 2.3.12 Non-selective β-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 2.5.1 Gastritis and peptic ulcer during pregnancy |
| Record Nr. | UNINA-9910458841103321 |
| Amsterdam ; ; New York, : Elsevier, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drugs during pregnancy and lactation [[electronic resource] ] : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer
| Drugs during pregnancy and lactation [[electronic resource] ] : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; New York, : Elsevier, 2007 |
| Descrizione fisica | 1 online resource (907 p.) |
| Disciplina | 618.32 |
| Altri autori (Persone) | SchaeferChristof |
| Soggetto topico |
Pregnant women - Drug use
Pregnant women - Medical care Obstetrical pharmacology Fetus - Effect of drugs on Newborn infants - Effect of drugs on |
| ISBN | 9780080549774 (Electronic Book) |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders
1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective β[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 2.3.12 Non-selective β-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 2.5.1 Gastritis and peptic ulcer during pregnancy |
| Record Nr. | UNINA-9910784615103321 |
| Amsterdam ; ; New York, : Elsevier, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drugs during pregnancy and lactation : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer
| Drugs during pregnancy and lactation : handbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease / / edited by Christof Schaefer |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Amsterdam ; ; New York, : Elsevier, 2007 |
| Descrizione fisica | 1 online resource (907 p.) |
| Disciplina | 618.32 |
| Altri autori (Persone) | SchaeferChristof |
| Soggetto topico |
Pregnant women - Drug use
Pregnant women - Medical care Obstetrical pharmacology Fetus - Effect of drugs on Newborn infants - Effect of drugs on |
| ISBN | 9780080549774 (Electronic Book) |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders
1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective β[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 2.3.12 Non-selective β-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 2.5.1 Gastritis and peptic ulcer during pregnancy |
| Record Nr. | UNINA-9910828812503321 |
| Amsterdam ; ; New York, : Elsevier, 2007 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
TRICARE [[electronic resource] ] : changes to access policies and payment rates for services provided by civilian obstetricians
| TRICARE [[electronic resource] ] : changes to access policies and payment rates for services provided by civilian obstetricians |
| Autore | Ekstrand Laurie E |
| Pubbl/distr/stampa | Washington, DC : , : U.S. Govt. Accountability Office, , [2007] |
| Descrizione fisica | 18 pages : digital, PDF file |
| Soggetto topico |
Managed care plans (Medical care) - United States
Obstetrics Pregnant women - Medical care |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | TRICARE |
| Record Nr. | UNINA-9910698362303321 |
Ekstrand Laurie E
|
||
| Washington, DC : , : U.S. Govt. Accountability Office, , [2007] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
